Structured page family:Cost guide
Exenatide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Exenatide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Byetta pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Exenatide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$700-$900/month
Average wholesale price
~$650-$800/month
Pharmacy acquisition estimate
~$600-$750/month
Typical negotiated rate
~$450-$650/month
Price per dose
~$12 per 5 mcg BID dose; ~$32 per weekly 2 mg
Annual cost at list price
~$8,400-$10,800
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Retail | $650-$900/month | Standard |
| GoodRx | $550-$800/month | Discounted |
Insurance Coverage Landscape
Commercial plans
~80-90% for T2D
Medicare Part D
Covered for T2D
Medicaid
Most states cover for T2D
VA coverage
On formulary
TRICARE
Covered
Employer plan typical tier
Tier 2-3; copay $30-75
Prior Authorization Guide
Required Documentation
- •T2D diagnosis
- •Metformin failure or intolerance
Common Denial Reasons
- •Not T2D
- •No metformin trial
Appeal Template Points
- •T2D with inadequate control
- •Metformin intolerance documented
Expected timeline: 3-5 days
Savings Programs and Patient Assistance
Bydureon/Byetta savings card
copayEligibility: Commercially insured
Savings: $25/month
Income limit: None
Enrollment: simple
AstraZeneca program
AstraZeneca PAP
manufacturerEligibility: Uninsured, ≤400% FPL
Savings: Free
Income limit: ≤400% FPL
Enrollment: moderate
Annual application
Generic and Biosimilar Status
No generic currently available
Expected: Limited generic competition expected; newer GLP-1s have reduced market demand
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| Byetta 5-10 mcg BID | $700 | $8,400 |
| Bydureon 2 mg weekly | $900 | $10,800 |
Annual Cost Projection
Year 1
$2,400-$10,800
Year 2
$2,400-$10,800
Year 3
$2,400-$10,800
Assumptions
- •T2D indication
- •Insurance coverage
Cost-Saving Strategies
- 1.Bydureon weekly may improve adherence vs BID dosing
- 2.Copay card reduces out-of-pocket
- 3.Often covered without prior auth after metformin
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | ~£100-150/month (~$130-190) | NHS |
Need help comparing exenatide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a exenatide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Exenatide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Exenatide Cost FAQ
Sources
- 1. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.Diabetes Care • 2005Claim type: clinicalView source →
- 2. FDA Information on ExenatideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.